DNDN Related Analyst EPS View

May 9, 2013 01:58 PM UPDATE: Stifel Nicolaus Downgrades Dendreon (DNDN) to Sell

Feb 25, 2013 02:05 PM Bearish Analyst Comments on Dendreon (DNDN)

Jan 30, 2013 09:57 AM Cantor Fitzgerald Raises Estimates and PT on Dendreon (DNDN) Ahead of Q4

Sep 5, 2012 08:32 AM Cantor Fitzgerald Maintains a 'Hold' on Dendreon (DNDN); Near Term Not Pretty

Jul 31, 2012 02:37 PM Barclays Cuts Numbers on Dendreon (DNDN); Facing An Uphill Battle Just To Gain Traction

Jul 31, 2012 09:04 AM Canaccord Genuity Cuts PT and Estimates on Dendreon (DNDN); Going Off the Rails on a Crazy Train

Jul 31, 2012 07:04 AM Jefferies Cuts Numbers on Dendreon (DNDN) After Poor Q2

Jul 31, 2012 06:32 AM Baird Lower Numbers on Dendreon (DNDN) But Says Restructuring the Right Move

Jul 30, 2012 03:15 PM Maxim Upgrades Dendreon (DNDN) as the Street is 'Too Bearish' Ahead of Q2 Results

Jul 17, 2012 09:10 AM RBC Capital Negative on Dendreon (DNDN) Ahead of Q2 Results

Jun 4, 2012 09:05 AM Wedbush Reiterates an 'Underperform' on Dendreon (DNDN); New Treatments in Prostate Cancer Could Leave Provenge Behind

May 23, 2012 08:53 AM Canaccord Genuity Maintains a 'Hold' on Dendreon (DNDN) After Meeting with Management

May 8, 2012 09:21 AM Canaccord Genuity Maintains a 'Hold' on Dendreon (DNDN); Cutting Estimates After Q1 Results

May 8, 2012 08:33 AM Leerink Swann Downgrades Dendreon (DNDN) to Market Perform; Modest Growth and Building Competition Becomes Concerning

Apr 20, 2012 10:05 AM Canaccord Genuity on Biotechnology: Q1 Earnings Preview - What To Expect

Feb 28, 2012 01:31 PM Canaccord Genuity Cuts Price Target on Dendreon (DNDN) After Q4, But Keeps Buy Rating

Feb 28, 2012 09:52 AM Goldman Sachs Said Q4 Call Again Raises Dendreon (DNDN) Provenge Concerns

Feb 27, 2012 03:46 PM Baird Maintains a 'Neutral' on Dendreon (DNDN); Provenge Inflection Point Still Lacking

Feb 27, 2012 01:34 PM Brean Murray Carret & Co. Debates Survival of Dendreon (DNDN) Long-Term with Oral Competition; Maintains 'Sell'

Feb 7, 2012 08:28 AM Canaccord Genuity Raises Numbers on Dendreon (DNDN); Provenge Outlook Improved on Low Likelihood of New XGEVA Approval